C9orf72 Immunogen for FTD and ALS Treatment

The patent employs active immunization where the patient's own immune system is stimulated to produce anti-DPR antibodies continuously. The immunogen (DPR peptide conjugated to carrier protein) serves as a persistent antigen that maintains ongoing immune response, eliminating the need for repeated administrations of pre-formed antibodies and ensuring sustained therapeutic levels without the sharp decline seen in passive immunization approaches.

The patent implements prophylactic immunization before disease onset or in early stages, where the immunogen is administered in advance to establish protective antibody levels. This preliminary action creates immune memory and ensures therapeutic antibodies are present before significant neuronal damage occurs, addressing both the speed of effect (immediate upon exposure to DPR) and duration (long-term through immune memory).

The patent uses a carrier protein as an intermediary to conjugate the DPR peptide immunogen. This carrier serves multiple functions: it enhances the immunogenicity of the small DPR peptide, facilitates proper presentation to the immune system, and can be selected to minimize adverse immune reactions. The carrier acts as a safe vehicle that delivers the therapeutic immunogen while reducing the risk of unwanted immune responses compared to using the DPR peptide alone.

The patent optimizes the length and composition of the DPR peptide repeat region in the immunogen. By carefully controlling the number of repeats (typically 15-30 repeats) and the specific amino acid sequence, the immunogenicity is enhanced while maintaining safety margins. This parameter optimization ensures the immunogen is sufficiently immunogenic to induce protective antibodies but not so immunogenic as to trigger harmful autoimmune reactions or excessive inflammation.

The patent combines the small DPR peptide (which provides specificity) with a large carrier protein (which provides immunogenicity) through chemical conjugation. This merging creates a hybrid immunogen where the DPR peptide region ensures antibodies bind specifically to DPR proteins in the brain, while the carrier protein component stimulates a robust immune response and high antibody titers. The two components work synergistically to resolve the contradiction between specificity and immunogenicity.

The immunogen is a composite structure consisting of the DPR peptide repeat sequence covalently linked to a carrier protein. This composite design leverages the complementary properties of both components: the DPR peptide provides the specific epitope recognition sequence that ensures antibodies target DPR proteins, while the carrier protein provides additional epitopes that stimulate strong B-cell activation and high antibody production. The composite nature allows simultaneous achievement of specificity and high immunogenicity.